Skip to main content
18 November 2026

Viatris Completes Acquisition of Pacira BioSciences

Viatris Inc. , a global healthcare company, announced that it has completed its acquisition of Pacira BioSciences, Inc. , a leader in non-opioid pain management.

"Today marks an important milestone in the execution of our strategy to strengthen our U.S. innovative medicines business," said Scott A. Smith, CEO of Viatris. "With Pacira now part of Viatris, we are bringing together complementary portfolios, capabilities and expertise to establish a leadership position in non-opioid pain management. We are excited to welcome our new Pacira colleagues as we create new opportunities to make a meaningful difference for patients and accelerate our path to sustained revenue and earnings growth."

Viatris' tender offer to purchase all of the issued and outstanding shares of common stock of Pacira, par value $0.001 per share (the "Shares"), for $36.50 per Share in cash, net of applicable withholding taxes and without interest, expired one minute after 11:59 p.m., Eastern Time, on Nov. 16, 2026 (the "Expiration Time"). Equiniti Trust Company, LLC, the depositary for the tender offer, has advised Viatris that approximately 32,929,780 Shares were validly tendered and not validly withdrawn in the tender offer, representing approximately 66.46% of the total outstanding Shares as of the Expiration Time. All conditions to the tender offer having been satisfied or waived on Nov. 17, 2026, Peach Purchaser Sub Inc. ("Purchaser"), a wholly owned subsidiary of Viatris, accepted for payment all Shares that were validly tendered and not validly withdrawn pursuant to the tender offer.

slot gacor